A Single-Blind Randomized Controlled Trial To Evaluate The Effect of 6 Months of Progressive Aerobic Exercise Training in Patients With Uraemic Restless Legs Syndrome
A Single-Blind Randomized Controlled Trial To Evaluate The Effect of 6 Months of Progressive Aerobic Exercise Training in Patients With Uraemic Restless Legs Syndrome
A Single-Blind Randomized Controlled Trial To Evaluate The Effect of 6 Months of Progressive Aerobic Exercise Training in Patients With Uraemic Restless Legs Syndrome
doi: 10.1093/ndt/gft288
Advance Access publication 8 August 2013
Christoforos D. Giannaki1,2,
Georgios M. Hadjigeorgiou2,3,
2,4
Christina Karatzaferi ,
Maria D. Maridaki5,
Yiannis Koutedakis ,
Trikala, Greece,
Paraskevi Founta ,
Nikolaos Tsianas6,
Greece,
Ioannis Stefanidis
2,7
2,4,7
Keywords: depression, exercise with no resistance, haemodialysis, sleep disorder, sleep quality
A B S T R AC T
Background. Uraemic restless legs syndrome (RLS) affects a
signicant proportion of patients receiving haemodialysis
(HD) therapy. Exercise training has been shown to improve
RLS symptoms in uraemic RLS patients; however, the mechanism of exercise-induced changes in RLS severity is still
unknown. The aim of the current randomized controlled
exercise trial was to investigate whether the reduction of RLS
severity, often seen after training, is due to expected systemic
exercise adaptations or it is mainly due to the relief that leg
movements confer during exercise training on a cycle ergometer. This is the rst randomized controlled exercise study
in uraemic RLS patients.
Methods. Twenty-four RLS HD patients were randomly assigned to two groups: the progressive exercise training group
(n = 12) and the control exercise with no resistance group
(n = 12). The exercise session in both groups included intradialytic cycling for 45 min at 50 rpm. However, only in the
progressive exercise training group was resistance applied, at
6065% of maximum exercise capacity, which was reassessed
every 4 weeks to account for the patients improvement.
The severity of RLS symptoms was evaluated using the
The Author 2013. Published by Oxford University Press on
behalf of ERA-EDTA. All rights reserved.
2834
2,4
ORIGINAL ARTICLE
Nicosia, Cyprus,
Ethics Committee at the University of Thessaly and the two hospitals, while all patients gave their written informed consent.
The inclusion criteria were dialysis for at least 3 months
with adequate dialysis delivery (Kt/V) and with stable clinical
condition. The exclusion criteria included diagnosed neuropathies or reasons for being in a catabolic state within 3 months
prior to the start of the study or being unable to exercise. None
of the recruited patients were engaged in any systematic exercise training programme, and none of them has been treated
with any medication for RLS prior to the study. A neurologist
skilled in RLS (GMH) examined the patients in order to assess
any potential augmentation phenomena during the study
period, using the standard criteria [9].
INTRODUCTION
Haemodialysis procedure
The patients received the HD therapy (Fresenius 4008B,
Oberursel, Germany) three times per week with low-ux,
hollow-ber dialysers and bicarbonate buffer, with each
session lasting 4 h. All patients had a forearm arteriovenous
stula as a vascular access to receive the HD treatment. An enoxaparin dose of 4060 mg was administered intravenously
before the beginning of each HD session. EPO therapy was
given after the completion of the HD session in order to normalize haemoglobin levels within 1112 (g/dL).
Subjects
Twenty-four uraemic RLS patients were recruited from the
HD units of the University Hospital of Larisa and the General
Hospital of Trikala, both located in the region of Thessaly in
central Greece. RLS diagnosis was based on the criteria set by the
International RLS Study Group (IRLSSG) [9], while the severity
of the symptoms was assessed using the IRLSSG severity rating
scale [10]. The study adhered to the Declaration of Helsinki and
ethical approval was obtained by the Human Research and
2835
ORIGINAL ARTICLE
12
12
Female/Male
3/9
4/8
Age (year)
59.2 11.8
58.0 10.7
BMI (kg/m )
27.7 3.6
26.5 4.4
Kt/V
1.1 0.0
1.2 0.0
Months in HD
24.0 15
30 26
Iron (g/dL)
55.0 37.0
72.2 17.9
Ferritin (ng/dL)
208.5 88.0
216.9 111.0
Hct
34.4 6.2
38.5 3.3
Hb (g/dL)
10.9 2.1
12.7 1.1
Albumin (g/dL)
4.1 0.2
4.4 0.4
BUN (mg/dL)
98 21
101 18
Phosphorus (mg/dL)
5.4 1.2
5.4 1.3
PTH (pg/mL)
312 212
298 289
Antihypertensive
8 (66%)
7 (58%)
Anticholesteraemic
6 (50%)
6 (50%)
Cardiac supportive
7 (58%)
8 (66%)
Peptic disease
therapy
2 (16%)
1 (8%)
Other
3 (25%)
5 (41%)
Diabetes prevalence
1 (8%)
1 (8%)
Cardiovascular disease
prevalence
2 (17%)
3 (25%)
Statistical analysis
The baseline values of each outcome measure were compared with the values obtained at 6 months by generalized
linear model (GLM) repeated measures. Categorical variables
were analysed using Chi-square analysis. Continuous variables
were analysed using an independent sample t-test. In the case
of outcome variables which changed in the same direction in
both the progressive exercise and control groups, betweengroup comparisons were also performed (comparing change values) to determine whether the change in one group
was signicantly greater than that of the other group. Spearmans rank correlation test was used to assess the relationships
between the examined variables. All statistical analyses were
performed using the SPSS version 18.0 (SPSS Inc. Chicago, Illinois). Data are presented as mean SD and the level of statistical signicance was set at P 0.05.
Medication
R E S U LT S
All of the patients successfully completed the 6-month intervention programme with no adverse effects and no augmentation phenomena to report. The patient characteristics at
baseline are presented in Table 1. No signicant differences in
the patients basic characteristics were found between the two
groups (P > 0.05). None of the basic characteristics were signicantly changed after the intervention period, except for the
Kt/V which signicantly improved in the progressive exercise
training group compared with its respective baseline value
(1.10 0.0 baseline versus 1.25 0.1 post exercise, P = 0.041).
In contrast, no signicant differences were found in Kt/V for
the control group (1.2 0.0 baseline versus 1.2 0.4 post exercise, P > 0.05). None of the biochemical indices measured in
the current study changed statistically after the 6 months intervention in either of the groups.
Changes in IRLS severity score, sleep quality, daily sleepiness and depression score are presented in Table 2. At baseline, no signicant differences were observed between the two
C. D. Giannaki et al.
Exercise
group
ORIGINAL ARTICLE
Biochemical assessment
The patients routine monthly laboratory results were recorded including iron, ferritin haematocrit, haemoglobin,
albumin and dialysis efciency parameters. A single-pool Kt/V
was calculated from pre- and post-dialysis BUN measurements
using the Daugirdas II equation [15] at baseline and at the end
of the 6-month intervention. The biochemical analysis was
performed at the clinical biochemistry laboratory of the University Hospital of Larissa under standard hospital procedures.
Variables
Exercise group
Control
group
Sleep Diary
Baseline
9.0 5.1
6-month post
7.2 4.3
10.7 3.5
P=0.038
9.4 3.1
Change
1.8 2.5
1.3 3.5
95% CI of
change
3.3 0.2
3.5 0.9
ESS
Baseline
5.0 2.7
7.8 5.3
6-month post
5.0 1.8
6.9 3.3
change
0.1 2.7
0.9 5.0
95% CI of
change
1.8 1.6
4.0 2.2
Baseline
6-month post
45.1 6.5
44.7 12.7
P=0.000
34.2 7.0
change
10.9 6.0#
95% CI of
change
14.7 7.0
P=0.020
43.7 6.7
Variables
1.0 11.6
8.3 6.3
IRLS score
25.4 9.3
22.0 7.2
6-month post
10.7 8.5P=0.003
18.3 7.8
change
14.7 7.9#P=0.007
3.6 7.1
95% CI of
change
19.7 9.6
8.1 0.9
Control
group
92.0 17.3#P=0.019
62.0 15.9
NSRI (seconds)
Baseline
Baseline
Exercise group
P=0.047
60.0 14.1
6-month post
82.3 26.0
Change
9.6 14.1
1.9 5.5
19.2 0.1
7.1 3.1
95% CI of
change
STS-5 (repetitions)
Baseline
6-month post
be signicantly better in the progressive exercise group compared with the control group.
Moreover, the -change values in sleep quality correlated
signicantly with the -change values in Kt/V (r = 0,946,
P = 0.000). Functional capacity was improved after the
6 months of the training regime however only in the Exercise
group compared to the control (Table 3).
10.7 2.0
9.1 0.7
8.5 2.5P=0.003
8.5 1.5
0.6 1.3
change
2.2 1.9
95% CI of
change
3.5 0.9
1.6 0.4
24.7 3.2
28.2 1.9
#P=0.045
STS-60 (s)
Baseline
6-month post
30.3 6.8
P=0.005
change
5.6 4.7#
95% CI of
change
9.0 2.1
P=0.052
30.0 2.2
1.7 2.7
4.2 0.8
All data are expressed as mean SD. STS-5, sit-to-stand test verepetitions; STS-60, sit-to-stand test 60 s; NSRI, North
Staffordshire royal inrmary test.
#
Signicantly different than the control group. Signicantly
different from the respective baseline value.
DISCUSSION
This is the rst randomized controlled exercise intervention
study investigating the effects of progressive exercise training
2837
ORIGINAL ARTICLE
month intervention. At baseline the two groups did not differ. The
progressive exercise training group improved signicantly (P = 0.003),
while no signicant changes were observed in the control group
(P > 0.05). After the intervention period there was a signicant difference between the groups (P = 0.017). All data are mean SD. IRLS,
International Restless Legs Syndrome severity rating scale; ns = nonsignicant differences.
ORIGINAL ARTICLE
C. D. Giannaki et al.
limited number of exercise sessions were characterized as incomplete, i.e. when the patients were unable to complete the
full 45 min cycling due to personal reasons. Unfortunately,
those events were not systematically recorded, thus we are
unable to comment on whether the level of compliance, which
we however gauge as very high, could affect the nal outcomes.
Finally, we were not able to assess the levels of -endorphin
during the course of the study or during an exercise bout and
have to thus rely on available bibliography to surmise a possible mechanism.
CONCLUSIONS
AC K N O W L E D G E M E N T S
We thank all HD patients who volunteered and participated in
this study as well as all the staff at the dialysis units of the University Hospital of Larissa, Greece and General Hospital of
Trikala, Greece for their expert advice and valuable help
during the course of the study.
C O N F L I C T O F I N T E R E S T S TAT E M E N T
None declared. The results presented in this paper have not
been published previously in whole or part, except in abstract
format.
REFERENCES
1. Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of
symptoms in end-stage renal disease: a systematic review. Adv
Chronic Kidney Dis 2007; 14: 8299
2. Giannaki CD, Sakkas GK, Karatzaferi C et al. Evidence of increased muscle atrophy and impaired quality of life parameters in
patients with uremic restless legs syndrome. PLoS One 2011; 6:
e25180
3. Mucsi I, Molnar MZ, Ambrus C et al. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis.
Nephrol Dial Transplant 2005; 20: 571577
2839
ORIGINAL ARTICLE
4. Unruh ML, Levey AS, DAmbrosio C et al. Restless legs symptoms among incident dialysis patients: association with lower
quality of life and shorter survival. Am J Kidney Dis 2004; 43:
900909
5. La Manna G, Pizza F, Persici E et al. Restless legs syndrome
enhances cardiovascular risk and mortality in patients with
end-stage kidney disease undergoing long-term haemodialysis
treatment. Nephrol Dial Transplant 2011; 26: 19761983
6. Giannaki CD, Zigoulis P, Karatzaferi C et al. Periodic limb movements in sleep contribute to further cardiac structure abnormalities in hemodialysis patients with restless legs syndrome. J Clin
Sleep Med 2013; 9: 147153
7. Garcia-Borreguero D, Allen RP, Benes H et al. Augmentation as a
treatment complication of restless legs syndrome: concept and
management. Mov Disord 2007; 22: S476SS84
8. Sakkas GK, Hadjigeorgiou GM, Karatzaferi C et al. Intradialytic
aerobic exercise training ameliorates symptoms of restless legs
syndrome and improves functional capacity in patients on hemodialysis: a pilot study. ASAIO J 2008; 54: 185190
9. Allen RP, Picchietti D, Hening WA et al. Restless legs syndrome:
diagnostic criteria, special considerations, and epidemiology. A
report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med
2003; 4: 101119
10. Walters AS, LeBrocq C, Dhar A et al. Validation of the International Restless Legs Syndrome Study Group rating scale for
restless legs syndrome. Sleep Med 2003; 4: 121132
11. Heyward V. Assessing Cardiorespiratory Fitness, 3rd ed.
Heyward: Human Kinetics, 1998
12. Gkizlis V, Giannaki CD, Karatzaferi C et al. Uremic versus idiopathic restless legs syndrome: impact on aspects related to quality
of life. ASAIO J 2012; 58: 607611
13. Zung WW. A self-rating depression scale. Arch Gen Psychiatry
1965; 12: 6370
14. Johns MW. A new method for measuring daytime sleepiness: the
Epworth sleepiness scale. Sleep 1991; 14: 540545
15. Daugirdas JT. Second generation logarithmic estimates of singlepool variable volume Kt/V: an analysis of error. J Am Soc
Nephrol 1993; 4: 12051213
16. Giannaki CD, Sakkas GK, Hadjigeorgiou GM et al. Non-pharmacological management of periodic limb movements during hemodialysis session in patients with uremic restless legs syndrome.
ASAIO J 2010; 56: 538542
17. Johansen KL, Painter P. Exercise in individuals with CKD. Am J
Kidney Dis 2012; 59: 126134
18. Esteves AM, de Mello MT, Pradella-Hallinan M et al. Effect of
acute and chronic physical exercise on patients with periodic leg
movements. Med Sci Sports Exerc 2009; 41: 237242
19. von Spiczak S, Whone AL, Hammers A et al. The role of opioids
in restless legs syndrome: an [11C]diprenorphine PET study.
Brain 2005; 128: 906917
20. Walters AS, Winkelmann J, Trenkwalder C et al. Long-term
follow-up on restless legs syndrome patients treated with opioids.
Mov Disord 2001; 16: 11051109
21. Chen WC, Lim PS, Wu WC et al. Sleep behavior disorders in a
large cohort of chinese (Taiwanese) patients maintained by longterm hemodialysis. Am J Kidney Dis 2006; 48: 277284
ORIGINAL ARTICLE
2840
C. D. Giannaki et al.